Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus adalimumab up to 48 weeks using a matching-adjusted indirect comparison

Background: The FUTURE 2 (F2) trial showed superiority of Secukinumab 150 mg and 300 mg over placebo (efficacy sustained to week 52). The ASEPT trial compared adalimumab 40 mg wih placebo in biologic-naive patients. There is no head-to-head-trial. Patients could switch from placebo (F2: week 16 or 24;[for full text, please go to the a.m. URL]
44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)